Tadnersen
RNA / oligonucleotide
Also known as BIIB078
Evidence outlook · program status
Discontinued, after a negative readout
Randomized, double-blind, placebo-controlled Phase 1 (NCT03626012) in C9orf72-associated ALS; no reduction in neurofilament, no benefit on clinical outcomes versus placebo; sponsor discontinued development. Follow-up study NCT04288856 terminated. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03626012 NCT03626012 · Amyotrophic Lateral Sclerosis Phase 1/2 study (n=106) in C9orf72 ALS showing no reduction in neurofilament light chain or slowing of functional decline; program discontinued for lack of efficacy (Lancet Neurol 2024). Its registered primary outcome on ClinicalTrials.gov is "Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak. Registry: NCT03626012 | 1 | Incidence of adverse events and serious adverse events 2021-11-17 | No clinical benefit or NfL reduction across dose cohorts; development discontinued | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.